{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:36:14Z","timestamp":1770896174197,"version":"3.50.1"},"reference-count":100,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2015,1,2]]},"DOI":"10.1517\/13543776.2014.982534","type":"journal-article","created":{"date-parts":[[2014,11,15]],"date-time":"2014-11-15T07:57:10Z","timestamp":1416038230000},"page":"17-31","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":36,"title":["An updated patent review of calpain inhibitors (2012 \u2013 2014)"],"prefix":"10.1517","volume":"25","author":[{"given":"Isaac O","family":"Donkor","sequence":"first","affiliation":[{"name":"The University of Tennessee Health Science Center","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,11,15]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvr070"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1538\/expanim.59.549"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/312566a0"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07451"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800045t"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(91)90015-P"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1016\/S0021-9258(17)34795-6","article-title":"Filamin-actin interaction. Dissociation of binding from gelation by Ca2+-activated proteolysis","volume":"253","author":"Davies PJ","year":"1978","unstructured":"Davies PJ, Wallach D, Willingham MC, et al. Filamin-actin interaction. Dissociation of binding from gelation by Ca2+-activated proteolysis. J Biol Chem 1978;253:4036-42","journal-title":"J Biol Chem"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.77.3.603"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(98)01697-4"},{"issue":"11","key":"e_1_3_2_12_1","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1242\/jcs.109.11.2715","article-title":"Talin contains three actin-binding sites each of which is adjacent to a vinculin-binding site","volume":"109","author":"Hemmings L","year":"1996","unstructured":"Hemmings L, Rees DJ, Ohanian V, et al. Talin contains three actin-binding sites each of which is adjacent to a vinculin-binding site. J Cell Sci 1996;109(Pt 11):2715-26","journal-title":"J Cell Sci"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.3.6.1146-1156.1983"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)91582-8"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)84966-9"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb06174.x"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3450129"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(97)00225-1"},{"key":"e_1_3_2_19_1","first-page":"75","volume-title":"Intracellular calcium-dependent proteolysis","author":"Crawford C","year":"1990","unstructured":"Crawford C. Protein and peptide inhibitors of calpain. In: Mellgren RL, Murachi T, editors. Intracellular calcium-dependent proteolysis. CRC, Boca Raton, FL; 1990. p. 75-89"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.12.4474-4481.2000"},{"key":"e_1_3_2_21_1","first-page":"103","volume-title":"Calpain: pharmacology and toxicology of calcium-dependent protease","author":"Fox JEB","year":"1999","unstructured":"Fox JEB, Saido TC. Calpain in signal transduction. In: Wang KKK, Yuen P-W, editors. Calpain: pharmacology and toxicology of calcium-dependent protease. Taylor and Francis, Philadelphia, PA; 1999. p. 103-26"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1006\/scdb.2000.0165"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/342505a0"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1006\/nlme.1998.3840"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.8.11.8070630"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90368-2"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2006.08.009"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.568480"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802610790725489"},{"key":"e_1_3_2_30_1","unstructured":"Universidad De Alcala. Derivatives of 5-azolones as calpain inhibitors. WO014314; 2013"},{"key":"e_1_3_2_31_1","unstructured":"Abbott GmbH & Co. Carboxamide compounds and their use as calpain inhibitors. US0286146; 2010"},{"key":"e_1_3_2_32_1","unstructured":"Abbott GmbH & Co. Carboxamide compounds and their use as calpain inhibitors. US7728012; 2010"},{"key":"e_1_3_2_33_1","unstructured":"Abbott Laboratories. Carboxamide compounds and their use as calpain inhibitors. US8283363; 2012"},{"key":"e_1_3_2_34_1","unstructured":"AbbVie Inc. Carboxamide compounds and their use as calpain inhibitors V. WO149800; 2013"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2013.09.002"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.13.6687"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1039\/C2MD00280A"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2014.07.004"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1367"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2003.12.016"},{"key":"e_1_3_2_41_1","unstructured":"Greenbaum DC. Novel \u03b1-helical peptidomimetic inhibitors and methods using same. WO163567; 2013"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja307599z"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2008.08.019"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867003374129"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.31.841"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)80319-X"},{"key":"e_1_3_2_47_1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1515\/BC.2007.117","article-title":"Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer\u2019s disease therapeutics","volume":"388","author":"Hook G","year":"2007","unstructured":"Hook G, Hook VY, Kindy M. Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer\u2019s disease therapeutics. Biol Chem 2007;388:979-83","journal-title":"Biol Chem"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4006719"},{"key":"e_1_3_2_49_1","unstructured":"Arancio O Fa M Schiefer IT Thatcher GR. Novel cysteine protease inhibitors and uses thereof. WO116663; 2013"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(83)80483-9"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M610372200"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/psc.2511"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313873200"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2014.05.058"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(00)00006-X"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-200012000-00007"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/089771501317095269"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2004.12.050"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02256121"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.060129"},{"key":"e_1_3_2_61_1","unstructured":"Banyan Biomarkers. Dipeptide calpain inhibitors. WO021788; 2012"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1021\/ol302850n"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2011.450"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300387"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/ol3002199"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/chem.201204260"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.201200320"},{"key":"e_1_3_2_68_1","unstructured":"Abell AD Chua K. Macrocyclic compounds and uses thereof. WO075146; 2014"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/292040"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2010.06.004"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0100"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31829c7370"},{"key":"e_1_3_2_73_1","unstructured":"Ishiguro S Ozaki H Nakazawa M Yamashita T. Mitochondrial calpain-inhibiting peptides and pharmaceuticals containing the peptides for prevention and treatment of retinal call degradation. JP047164; 2014"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2012.07.018"},{"key":"e_1_3_2_75_1","first-page":"269","article-title":"Calpain II in human lens","volume":"30","author":"David LD","year":"1989","unstructured":"David LD, Varnum MD, Lampi KJ, Shearer TR. Calpain II in human lens. Invest Ophthalmol Vis Sci 1989;30:269-75","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-1291"},{"key":"e_1_3_2_77_1","first-page":"2255","article-title":"A human lens model of cortical cataract: Ca2+-induced protein loss, vimentin cleavage and opacification","volume":"41","author":"Sanderson J","year":"2000","unstructured":"Sanderson J, Marcantonio JM, Duncan G. A human lens model of cortical cataract: Ca2+-induced protein loss, vimentin cleavage and opacification. Invest Ophthalmol Vis Sci 2000;41:2255-61","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_78_1","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/anie.200805014","article-title":"Molecular modeling, synthesis and biological evaluation of macrocyclic calpain inhibitors","volume":"48","author":"Abell AD","year":"2009","unstructured":"Abell AD, Coxon JM, Jones MA, et al. Molecular modeling, synthesis and biological evaluation of macrocyclic calpain inhibitors. Angew Chem Int Ed Engl 2009;48:1455-8","journal-title":"Angew Chem Int Ed Engl"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-11088"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033391649"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(91)90052-2"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)35804-6"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2900191"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.7.2628"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/35012636"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207426200"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00627-5"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00259-9"},{"key":"e_1_3_2_89_1","unstructured":"Kwon Y Lee E. Undecylenate and conjugated linoleate for the treatment of neurological disorders. WO026662; 2012"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2012.01.015"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp236"},{"key":"e_1_3_2_92_1","unstructured":"Richard I Charton K. Calpain-3 inhibitors for treating muscular dystrophies and cardiomyopathies. US0171172; 2013"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/8385"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.151.7.1583"},{"key":"e_1_3_2_95_1","unstructured":"Nemirovskaya TL Lomonosova YN. Method for preventing and reducing destruction of skeletal muscle proteins in atrophy caused by hypokinesia and\/or gravisensing. RU2517576 C1 0527; 2014"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20121008"},{"key":"e_1_3_2_97_1","unstructured":"Chishti A. Identification and use of protease inhibitors to treat or prevent sickle disease. WO067415; 2013"},{"key":"e_1_3_2_98_1","unstructured":"Peyron J-F Lagadec P. Methods for monitoring the response to treatment and for treating colorectal cancer. WO110425; 2012"},{"key":"e_1_3_2_99_1","unstructured":"INSERM. Methods and pharmaceutical compositions for prevention of aging-related lesions. WO096087; 2014"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvs232"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2004.06.001"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2006.02.017"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543776.2014.982534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:54:31Z","timestamp":1770893671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543776.2014.982534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,15]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,2]]}},"alternative-id":["10.1517\/13543776.2014.982534"],"URL":"https:\/\/doi.org\/10.1517\/13543776.2014.982534","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}